SOURCE: Pacific Biometrics, Inc.

September 12, 2008 08:50 ET

Pacific Biometrics, Inc. to Exhibit at 30th Annual Meeting of American Society for Bone and Mineral Research

SEATTLE, WA--(Marketwire - September 12, 2008) - Pacific Biometrics, Inc. (OTCBB: PBME), a leading provider of specialty medical laboratory and biomarker assay development and testing services, today announced that it will exhibit its laboratory and contract research services, along with its biomarker assay capabilities, at the 30th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR). The meeting will be held September 12-16, 2008 at the Palais des congres de Montréal in Montréal, Quebec, Canada.

The ASBMR Annual Meeting, the premier meeting for bone and mineral science, will be attended by more than 5,000 clinicians and researchers from around the world. Pacific Biometrics will be exhibiting at Booth #816 at the ASBMR meeting.

"Pacific Biometrics has been a leader in providing specialty assay services for bone and cartilage markers to the pharmaceutical and biotech industry for many years," commented Ron Helm, Chairman and Chief Executive Officer of the Company. "In many ways, bone markers are a type of biomarker in the osteoporosis and arthritis fields, and we intend to leverage our experience in this area to capture a significant share of the expanding market for clinical biomarker services. In fact, at our ASBMR booth, we will showcase our new menu of biomarker assay development services, which is being spearheaded by our new wholly owned subsidiary, Pacific Biomarkers."


The American Society for Bone and Mineral Research (ASBMR) is a professional, scientific and medical society established to promote excellence in bone and mineral research and to facilitate the translation of that research into clinical practice. ASBMR has a membership of nearly 4,000 physicians, basic research scientists and clinical investigators from over 50 countries. A pioneering leader in the field of bone and mineral metabolism, ASBMR remains true to its original purpose of promoting bone and mineral research and nurturing young investigators, while fostering the integration of clinical and basic science, and facilitating the translation of that science to health care and clinical practice. ASBMR publishes the Journal of Bone and Mineral Research and the Primer on Metabolic Bone Disease and Disorders of Mineral Metabolism.

About Pacific Biometrics, Inc.

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biomarkers, Inc., incorporated February 1, 2008 as a wholly owned subsidiary of Pacific Biometrics, Inc., focuses specifically on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing.

For more information about Pacific Biometrics, visit the Company's web site at The Company is headquartered in Seattle, Washington and its common stock trades on the OTC Bulletin Board under the symbol "PBME."

Safe Harbor Statement

This press release includes forward-looking statements including, but not limited to, the growth in revenues and backlog that may result from the Company's established and new services, its strategic planning and business development plans, impacts on its financial results, future growth, and the viability and acceptance of its products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the Company's ability to bid on and win laboratory services contracts, the success of its marketing and business development efforts, competition in the industry, and its ability to manage growth, as well as the risks and other factors set forth in its periodic filings with the U.S. Securities and Exchange Commission (including the Form 10-KSB for the year ended June 30, 2007, and Forms 10-QSB for the quarters ended September 30, 2007, December 31, 2007 and March 31, 2008).

Contact Information

  • For Additional Information, Please Contact:
    Ron Helm
    Chairman and CEO
    (206) 298-0068
    R. Jerry Falkner
    RJ Falkner & Company, Inc.
    Investor Relations Counsel
    (800) 377-9893
    Email Contact